188582-62-9Relevant articles and documents
Liquid crystal compound
-
Paragraph 0358-0359, (2020/06/03)
PROBLEM TO BE SOLVED: To provide a compound exhibiting high dissolubility in a liquid crystal composition and high storage stability, and a liquid crystal composition and a liquid crystal display element containing the compound as a constitutional member. SOLUTION: There are provided 4-ethoxy-4'-methoxymethyl-2,3,3'-trifluorobiphenyl capable of being synthesized for example by reduction of a formyl group from 2-fluoro-4-bromobenzaldehyde, etherification and coupling with an organic boron compound like a following formula, and 4-ethoxy-4'-methoxypropyl-2,3,3'-trifluorobiphenyl capable of being synthesized by a similar method. SELECTED DRAWING: None COPYRIGHT: (C)2020,JPOandINPIT
Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease
Rabal, Obdulia,Sánchez-Arias, Juan A.,Cuadrado-Tejedor, Mar,de Miguel, Irene,Pérez-González, Marta,García-Barroso, Carolina,Ugarte, Ana,Estella-Hermoso de Mendoza, Ander,Sáez, Elena,Espelosin, Maria,Ursua, Susana,Haizhong, Tan,Wei, Wu,Musheng, Xu,Garcia-Osta, Ana,Oyarzabal, Julen
supporting information, p. 506 - 524 (2018/03/21)
We have identified chemical probes that act as dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors (>1 log unit difference versus class I HDACs) to decipher the contribution of HDAC isoforms to the positive impact of dua
SUBSTITUTED OXAZOLE- AND THIAZOLE-BASED CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS II
-
Page/Page column 26, (2016/06/14)
The invention relates to oxazole and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.